BAX - Baxter International Inc.

NYSE - NYSE Delayed Price. Currency in USD
74.70
-0.05 (-0.07%)
At close: 4:01PM EDT

74.71 +0.01 (0.01%)
After hours: 5:19PM EDT

Stock chart is not supported by your current browser
Previous Close74.75
Open74.80
Bid73.75 x 800
Ask76.00 x 2200
Day's Range74.32 - 74.85
52 Week Range58.81 - 75.62
Volume1,746,754
Avg. Volume2,839,492
Market Cap40.001B
Beta1.11
PE Ratio (TTM)49.87
EPS (TTM)1.50
Earnings DateJul 26, 2018
Forward Dividend & Yield0.76 (1.02%)
Ex-Dividend Date2018-05-31
1y Target Est78.86
Trade prices are not sourced from all markets
  • Baxter CEO on what's driving his company's stock price to...
    CNBC Videoslast month

    Baxter CEO on what's driving his company's stock price to...

    Baxter CEO Jose Almeida discusses future M&A, new product launches, and gearing up for hurricane season with CNBC's Meg Tirrell.

  • Business Wireyesterday

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share of common stock. The indicated annual dividend rate is $0.76 per share of common stock. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

  • See what the IHS Markit Score report has to say about Baxter International Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Baxter International Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $51 million.

  • Trump's APAC Focus Puts Spotlight on These 3 MedTech Stocks
    Zacks5 days ago

    Trump's APAC Focus Puts Spotlight on These 3 MedTech Stocks

    Despite the trade war upheaval in Asia, some medical device companies stand strong in the APAC region.

  • Can International Sales Drive Baxter's (BAX) Q2 Earnings?
    Zacks8 days ago

    Can International Sales Drive Baxter's (BAX) Q2 Earnings?

    Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.

  • Here's Why You Should Invest in Baxter (BAX) Stock Right Now
    Zacks13 days ago

    Here's Why You Should Invest in Baxter (BAX) Stock Right Now

    Baxter's (BAX) raised 2018 guidance and strong international presence make it a lucrative pick.

  • ACCESSWIRE13 days ago

    Complimentary Technical Snapshots on Akers Biosciences and Two More Medical Supplies Stocks

    Stock Research Monitor: ATRS and BAX LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration . On Tuesday, July 03, 2018, US ...

  • HRC or BAX: Which Is the Better Value Stock Right Now?
    Zacks14 days ago

    HRC or BAX: Which Is the Better Value Stock Right Now?

    HRC vs. BAX: Which Stock Is the Better Value Option?

  • Business Wire15 days ago

    Baxter to Host Second Quarter 2018 Financial Results Conference Call for Investors

    Baxter International (BAX), will host a conference call to discuss its second quarter 2018 financial results on Thursday, July 26, 2018, at 7:30 a.m. Central Time. The Conference ID is 2998733. Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.

  • Stryker or Baxter: Which is a Better Pick for Your Portfolio?
    Zacks16 days ago

    Stryker or Baxter: Which is a Better Pick for Your Portfolio?

    Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.

  • 5 Stocks Near 52-Week High: Is More Upside in the Cards?
    Zacks19 days ago

    5 Stocks Near 52-Week High: Is More Upside in the Cards?

    Here are some stocks trading near their 52-week high levels with potential to scale higher.

  • Business Wire20 days ago

    Baxter Releases 2017 Corporate Responsibility Report and Reinforces Its Commitment to Enriching Communities Around the World

    Baxter International Inc. (BAX), a leading global medical products company, today released its 2017 Corporate Responsibility Report, highlighting its efforts to create lasting social, economic and environmental value in the communities the company serves around the world. The report underscores Baxter’s progress toward its 2020 Corporate Responsibility priorities and goals, which span from reducing Baxter’s environmental footprint to addressing healthcare needs within underserved communities. “Responsible corporate citizenship goes hand in hand with our mission to save and sustain lives.

  • See what the IHS Markit Score report has to say about Baxter International Inc.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Baxter International Inc.

    Baxter International Inc NYSE:BAX

  • A Look At The Fair Value Of Baxter International Inc (NYSE:BAX)
    Simply Wall St.27 days ago

    A Look At The Fair Value Of Baxter International Inc (NYSE:BAX)

    I am going to run you through how I calculated the intrinsic value of Baxter International Inc (NYSE:BAX) by taking the expected future cash flows and discounting them to today’sRead More...

  • BSX or BAX: Which is a Better Pick for Your Portfolio Now?
    Zacks28 days ago

    BSX or BAX: Which is a Better Pick for Your Portfolio Now?

    After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

  • Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
    Zackslast month

    Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

    Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

  • Boston Scientific’s Valuations and Price Performance
    Market Realistlast month

    Boston Scientific’s Valuations and Price Performance

    Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.

  • Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?
    Zackslast month

    Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?

    Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.

  • Analyzing Baxter International’s Stock Repurchases and Cash Flows
    Market Realistlast month

    Analyzing Baxter International’s Stock Repurchases and Cash Flows

    Baxter International (BAX) has been regularly carrying out stock repurchases, a positive sign for investors. Baxter International generated $447 million from operating activities in the first quarter of 2018 compared to $206 million in Q1 2017. Baxter’s days payable outstanding increased from 48.6 days in Q1 2017 to 57.8 days in Q1 2018.

  • Baxter International’s Financial Performance
    Market Realistlast month

    Baxter International’s Financial Performance

    Baxter International (BAX) generated net sales of $2.7 billion in the first quarter of 2018 compared to $2.5 billion in Q1 2017. Baxter’s gross margins were affected by a negative impact from foreign exchange rates and the impact of lost sales due to Hurricane Maria and incremental supply chain costs in the first quarter. The company’s gross profit increased marginally from $1 billion in Q1 2017 to $1.1 billion in Q1 2018.

  • A Close Look at Baxter International’s Acquisitions
    Market Realistlast month

    A Close Look at Baxter International’s Acquisitions

    Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018 on the back of higher demand for Baxter’s CRRT (continuous renal replacement therapies) systems. In July 2017, Baxter International acquired Claris Lifesciences’ subsidiary Claris Injectables for a cash consideration of $629 million. Through this acquisition, Baxter gained capabilities in the production of essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives, and critical care in bags, vials, and ampoules.

  • Analyzing Baxter International’s Geographic Segments
    Market Realistlast month

    Analyzing Baxter International’s Geographic Segments

    Baxter generates a major part of its revenues from the Americas segment, which contributed $1.44 billion to the company’s total revenues in the first quarter, from $1.37 billion in Q1 2017. The company generated $724 million of revenue from its EMEA segment in the first quarter of 2018 compared to $631 million in the first quarter of 2017.

  • Baxter International’s Global Business Units in Q1 2018
    Market Realistlast month

    Baxter International’s Global Business Units in Q1 2018

    Baxter International’s (BAX) global business units include the following: Renal Care: peritoneal dialysis and hemodialysis therapies Medication Delivery: intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices Pharmaceuticals: premixed and oncology drug platforms, inhaled anesthesia, critical care products, and pharmacy compounding services Nutrition: parenteral nutrition therapies Advanced Surgery: biological products, medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention Acute Therapies and Other: continuous ...

  • How Much Upside Do Analysts See in Baxter Stock?
    Market Realistlast month

    How Much Upside Do Analysts See in Baxter Stock?

    Baxter International (BAX) provides a broad portfolio of essential healthcare products. Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.